44 results on '"VanDevanter, D.R."'
Search Results
2. Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis
3. Building global development strategies for cf therapeutics during a transitional cftr modulator era
4. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)
5. Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact
6. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection
7. Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact.
8. WS03.05 Multicenter validation of the cystic fibrosis-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis
9. P096 Effect of acute systemic corticosteroids on clinical outcomes in cystic fibrosis pulmonary exacerbations
10. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa
11. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis
12. Multicenter Validation of the CF-ABLE Score as a Predictor of Outcome and Therapeutic Response in Cystic Fibrosis
13. Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials
14. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis
15. Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation
16. WS01.01 Antipseudomonal treatment decisions during cystic fibrosis exacerbation management
17. Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint
18. Important steps in the journey to highly effective CFTR modulator access for people with CF
19. Pure chromosome-specific PCR libraries from single sorted chromosomes
20. P094 Design, enrollment, and feasibility of the STOP-2 randomised study of intravenous antibiotic treatment duration in cystic fibrosis pulmonary exacerbations
21. Another step in the journey: From CFTR mutation to sweat chloride concentration to survival
22. EPS7.7 Microbiologic changes in CF patients with chronic P. aeruginosa airway infection after 6 cycles of inhaled levofloxacin
23. WS23.4 IV antibiotic treatment of <9 days and treatment at home for CF pulmonary exacerbation are associated with increased odds of IV retreatment within 30 days
24. 37 Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection
25. 38 History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin
26. 186 Manifestation and progression of illness in young children with cystic fibrosis: A targeted literature review
27. WS07.1 Standardized treatment of pulmonary exacerbations (STOP) study: Treatment goals for pulmonary exacerbations
28. 311 Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis
29. 188 Standardized treatment of pulmonary exacerbations (STOP) study: Clinical presentations of pulmonary exacerbations
30. 189 Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response
31. 117 Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis clinical trials
32. WS7.6 Incorporation of a third inhaled antipseudomonal antibiotic class into the management of patients at an adult CF care center
33. WS3.4 Lack of correlation between sputum Pseudomonas aeruginosa density and FEV1 changes among CF patients treated with inhaled antibiotics
34. WS12.1 Evidence of diminished FEV1 in CF 6-year-olds followed in the European CF registry, 2007–2009
35. WS24.5 Unresponsive patients benefit from switching intravenous antibiotic treatments for pulmonary exacerbation
36. 180 Choice of IV vs. non-IV antibiotics for treating pulmonary exacerbations in patients with cystic fibrosis
37. 337 Changing incidence and thresholds for pulmonary exacerbation treatment, North America 1995-2005
38. Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint
39. Rate Of Lung Function Decline As An Outcome For Randomized Controlled Trials In Cystic Fibrosis
40. Sample size estimation for CF clinical trials using rate of lung function decline (RLFD) as an efficacy endpoint
41. Cloning of the LamA3 gene encoding the alpha 3 chain of the adhesive ligand epiligrin. Expression in wound repair.
42. 59. In vitro assessment of bactericidal activity and relevance to pharmacodynamics of aerosolized antibiotics
43. WS12.1 Evidence of diminished FEV1 in CF 6-year-olds followed in the European CF registry, 2007–2009.
44. Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.